A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)
Status:
Completed
Trial end date:
2013-05-23
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, multiple-rising-dose study will evaluate
the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-8150 in healthy young
men, in male participants with mild to moderate hypertension, in elderly male and female
participants with mild to moderate hypertension, and in male and female participants with
resistant hypertension. A primary study hypothesis is that there is at least one dose that
does not increase heart rate (HR) to a clinically meaningful extent in male participants with
mild to moderate hypertension and in elderly participants with mild to moderate hypertension
on either Day 1 or the last Day of multiple dosing (Daylast), as measured by Time-weighted
Average Across 24 hours (TWA0-24hrs). The hypothesis is met if mean increase (MK-8150 -
placebo) in TWA0-24hrs HR in the identified groups is ≤15 beats per minute on Day 1 and
Daylast.